Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sixth dose pertussis-containing vaccine booster in 11–12-year-old children
jRCTs071260056Recruiting
- Sponsor
- Research Foundation for Microbial Diseases of Osaka University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride in pertussis, diphtheria and Tetanus, sponsored by Research Foundation for Microbial Diseases of Osaka University. Primary endpoint: Primary immunogenicity endpoint. Started Jul 2026; status: recruiting.
02
Drugs
bismuth subcitrate potassium + metronidazole + tetracycline hydrochloride
03
Conditions
pertussisdiphtheriaTetanus
Beyond the preview
Go deeper on jRCTs071260056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071260056.